Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely

Executive Summary

Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.

You may also be interested in...



Biden’s Moves On AstraZeneca Stockpile Underscore Power Of Vaccine Diplomacy

America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.

The More Things Change: The Return Of David Kessler To Capitol Hill

A Senate hearing on the US COVID-19 response recalled Kessler’s tenure as FDA commissioner a quarter century ago – and included some reminders that things have changed.

Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable

Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel